this is not a play on whether or not this drug works.
we know it works as well and even better in some indications than blockbuster drug erbitux.
erbitux has severe side affects which often require hospitalization.
nimotuzumab causes nausea about 22% of the time.
which drug would you like to take?
32 phase 2/3 trials by a consortium of licensees all of whom have agreed to share all data. that's a lot of pr's coming our way.
this is a smart management team.
11 phase 2/3 trials by ym and it's direct licensees.
nimotuzumab is already approved in 23 countries including india, malaysia, singapore, and recently, mexico. you can get special access in some parts of europe.
do you think the current administration is not going to approve its use here?
this is a play on getting the go ahead from ofac to market a proven drug. when that happens ymi is a 10 dollar stock. it will be up every day.
overnight ymi will be in the crosshairs of major pharma.
some people know this and want your stock.
the people i know were buying hgsi, kerx, gnvc, aen, and rnn all under a buck.
i am told that ymi is the one bio that will be in the league of hgsi and dndn.
the playing field has now been leveled.
have a great day!
yeah,I understand. Used to own HGSI,bought around $2.69 and sold verieties after the new of LUPUs. Used to watch DNDN around $2. as well.didn't have money by then. anyway I just open my position with YMI today with a small position. Just wondering about Canadian stock VS Our American Stock....concern about management mainly....any opinion on that...I'll appreciated it
Exactly. And, this news could happen any day. Not to mention this application has non-partisan support along with President Obama. BTW YMI will be much bigger than DNDN check the link below.
"We are most appreciative of the extensive support we have received for our application from SCFR Chairman Senator John Kerry (D-MA), Western Hemisphere Subcommittee Chairman Senator Chris Dodd
(D-CT) and SCFR Ranking Member Senator Richard Lugar (R-IN) and for
their acute understanding of the needs of cancer patients. Such licenses have been previously granted to two companies seeking to commercialize
Cuban-origin therapeutics in the US and we have ongoing discussions with OFAC in
Excellent post with one caveat.
"do you think the current administration is not going to approve its use here?"
Remember, YMI will have to work with the FDA to gain US approval (where the real $ is). The operation word (and hazard) in this statement is 'FDA'. Anyone who has dealt with them, particularly from a small biopharma perspective, will tell you horror stories about the capriciousness of that regulatory body...common sense and logic are often not enough to carry the day.
well, not really.
and the fda has already given them the go ahead to enroll patients at us clinical sites for 2 ongoing phase 2 trials.
this will expand to some of the phase 3's.
with the degree of success being documented in over 9000 people worldwide, fda approval isn't the issue.
the unrestricted license from ofac is.
upon this big pharma will step in.
have a great day!